Dallah Healthcare Company SJSC

Dallah Healthcare maintains a debt-to-equity ratio of 0.96, indicating a balanced capital structure with moderate leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.24, suggesting it can cover short-term obligations but with limited buffer. Free cash flow stands at SAR 87.09 million, which is significantly lower than operating cash flow of SAR 555.39 million, indicating capital expenditures are consuming a large portion of operating cash.

Profitability metrics show a return on equity (ROE) of 13.19% and a return on assets (ROA) of 5.89%, both exceeding the industry median for healthcare facilities and services. The operating margin of 15.87% (calculated from operating income of SAR 645.42 million on revenue of SAR 4.07 billion) is robust, reflecting efficient cost management and pricing power.

Geographically, Dallah Healthcare's revenue is concentrated in Saudi Arabia, with no disclosed international operations. Segment-wise, the company operates as a single business unit, with no material diversification across product lines or geographic regions. This concentration increases exposure to local economic and regulatory shifts.

The company's revenue growth outlook for the current fiscal year is positive, with a projected increase of 4.2% year-over-year. Looking ahead, the next fiscal year is expected to see a 3.8% growth in revenue, driven by expansion in outpatient services and pharmaceutical distribution. These projections are supported by a historical revenue growth rate of 2.1% over the past three years.

Risk factors include a negative net cash position after subtracting total debt, which could constrain operational flexibility. The company's liquidity risk is moderate, with cash and equivalents of SAR 114 million against long-term debt of SAR 3.93 billion. Dilution risk is low, with no near-term pressure from share issuance, and the diluted shares outstanding are equal to the basic shares, indicating no material dilution potential.

Recent events include the filing of the latest financial report, which disclosed a 12.3% increase in outpatient services revenue and a 7.8% increase in pharmaceutical sales. No material earnings call transcripts or regulatory filings were disclosed in the latest data update.